Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06638944 · ClinicalTrials.gov registry record · Phase 2
Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease
A Phase 2 study of Stroke and Parkinson Disease, sponsored by Purdue University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT06638944: Recruiting Phase 2 study of Stroke and Parkinson Disease, sponsored by Purdue University.
NCT06638944 is a Phase 2 study of Stroke and Parkinson Disease that is actively recruiting participants, run by Purdue University. The registered enrollment target is 120 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06638944, a Phase 2 study of Stroke and Parkinson Disease, is actively recruiting participants, sponsored by Purdue University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
Dysphagia, or difficulty swallowing, is a common symptom of many neurological diseases but its treatment is not well established or easily accessible. To start addressing this gap, the researchers developed and validated a cost-effective wearable surface electromyography (sEMG) biofeedback sensor technology (i-Phagia), optimized to record muscle activity from the head/neck and provide biofeedback to patients and adherence data to clinicians during swallow therapy. This system has been developed with commercially available and widely used materials and the Purdue University IRB has determined that the device is non-significant risk device. The goal of this clinical trial is to learn if this biofeedback (using this new technology/i-Phagia) when used as an adjunct to a standard swallow therapy protocol works to improve swallowing function in patients post chronic stroke or diagnosed with Parkinson's disease. It will also help the investigators learn whether this therapy protocol is equally effective when provided in-person versus via telehealth. Finally, it will determine which patient factors may influence how well the treatment works. The main questions it aims to answer are: * Does biofeedback (using this new technology/i-Phagia) when used as an adjunct to a standard swallow therapy protocol works better than a standard of care treatment to improve swallowing function in patients post chronic stroke or diagnosed with Parkinson's disease? * Is completing the swallow therapy protocol at home (via telehealth) as effective as completing it in-person (in the clinic)? * What factors related to the patients (e.g., age, diagnosis, etc.) may influence how well the treatment works? Participants will: * Complete a 12-week swallow treatment protocol (12 treatment visits) either in-person or at home (via telehealth) * Complete 3 in-person evaluations (pre-treatment; post-treatment; and at a 12-week post treatment follow-up time point) * Exercise at home several days per we
Primary Outcome
The Penetration Aspiration Scale (PAS) is an 8-point scale, where 1 indicates a completely safe swallow without any penetration or aspiration present, and 8 indicates the most severe degree of aspiration with no attempt to clear the aspirated material. The PAS will be rated by trained investigators blinded to group/arm and time.
Conditions Studied
Interventions
- BEHAVIORAL In-person sEMG-biofeedback
- BEHAVIORAL Remote sEMG-biofeedback
- BEHAVIORAL Standard-of-care treatment
Study Locations (1)
Indiana
- Purdue University - West Lafayette
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-07-22 |
| Est. Completion | 2029-04-30 |
| Phase | Phase 2 |
What NCT06638944 shows while recruiting
NCT06638944 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Stroke appearing as the primary indexed condition, and to 3 interventions - of which In-person sEMG-biofeedback is the first listed.
NCT06638944 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT06638944 about?
NCT06638944 is a clinical study titled "Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease". Dysphagia, or difficulty swallowing, is a common symptom of many neurological diseases but its treatment is not well established or easily accessible. To start addressing this gap, the researchers developed and validated a cost-effective wearable surface electromyography (sEMG) biofeedback sensor t...
What is the current status of trial NCT06638944?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2025-07-22. Estimated completion is 2029-04-30.
What conditions does trial NCT06638944 study?
This clinical trial studies the following conditions: Stroke, Parkinson Disease, Dysphagia.
What interventions are being tested in trial NCT06638944?
The interventions under investigation include: In-person sEMG-biofeedback (BEHAVIORAL), Remote sEMG-biofeedback (BEHAVIORAL), Standard-of-care treatment (BEHAVIORAL).
Who is sponsoring clinical trial NCT06638944?
This trial is sponsored by Purdue University, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06638944 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06638944's enrollment target sits among peer trials
120 117th of 454 higher than 329 of 454 other Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Balancing Effortful and Errorless Learning in Naming Treatment for Aphasia
RECRUITING · Phase 2
-
Transcranial Magnetic Stimulation + Language Therapy to Treat Mild Aphasia
RECRUITING · Phase 2
-
Novel Wrist Sensor System to Promote Hemiparetic Arm Use in Home Daily Life of Chronic Stroke Survivors
RECRUITING · Phase 2
-
Transcranial Magnetic Stimulation + Language Therapy to Treat Subacute Aphasia
RECRUITING · Phase 2
-
Myofascial Dysfunction in Post Stroke Shoulder Pain
RECRUITING · Phase 2
-
Escitalopram and Language Intervention for Subacute Aphasia
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI